Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ligelizumab - Novartis

Next Previous
X
Search
Drug Profile

Ligelizumab - Novartis

Alternative Names: QGE-031

Latest Information Update: 15 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunoglobulin E inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Food hypersensitivity; Peanut hypersensitivity
  • Discontinued Allergic asthma; Atopic dermatitis; Bullous pemphigoid; Chronic urticaria; Hypersensitivity

Most Recent Events

  • 05 Apr 2023 Discontinued - Phase-II for Chronic-urticaria (In adolescents, In children) in Taiwan, Switzerland, Spain, Germany (SC) before March 2023
  • 05 Apr 2023 Discontinued - Phase-III for Chronic-urticaria (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in Brazil (SC) before March 2023
  • 05 Apr 2023 Discontinued - Phase-III for Chronic-urticaria (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in Colombia, Canada, Bulgaria, Argentina, Austria, Czech Republic, Germany, Greece, Guatemala, Finland, Estonia, Denmark, India, South Korea, Malaysia, Oman, Peru, Poland, Russia, Singapore, South Africa, Spain, Sweden, Thailand, Turkey, Hungary, USA, Australia, Belgium, Chile, Israel, Italy, Japan, Lebanon, Netherlands, Philippines, Romania, Slovakia, Taiwan, Tunisia, Vietnam (SC) before March 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top